📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
1 analysed today
FollowTelegram
1
Today
151,861
All-time analysed
43,535
Positive
6,743
Negative
92,746
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
28 announcements match the current filters (relevance ≥ 5).
Nectar Lifesciences Completes Buyback of 3 Crore Equity Shares at ₹27 Each
Nectar Lifesciences Limited (NECLIFE) has successfully concluded its share buyback program, repurchasing 3,00,00,000 equity shares. The buyback was executed at a price of ₹27 per share, with the tendering period ending on January 6, 2026. Settlement for all accepted shares was finalized on January 13, 2026, and the company is now in the process of extinguishing these shares. This reduction in the total number of outstanding shares is expected to improve the company's Earnings Per Share (EPS) and other financial ratios.
Key Highlights
Repurchased a total of 3,00,00,000 (3 Crore) equity shares via the tender offer route.
The buyback price was fixed at ₹27 per equity share.
Settlement of all validly tendered and accepted bids was completed on January 13, 2026.
The company is currently in the process of extinguishing the repurchased shares to reduce its equity base.
👀 What to Watch
The buyback is now complete, and the reduced share count should theoretically boost future EPS. Existing shareholders should monitor the company's next earnings report to see the impact of the reduced equity base on valuation metrics.
Nectar Lifesciences Announces ₹81 Crore Share Buyback at ₹27 Per Share via Tender Offer
Nectar Lifesciences Limited (NECLIFE) is executing a buyback of up to 3,00,00,000 equity shares, representing 13.38% of its total paid-up equity capital. The buyback is priced at ₹27 per share, involving a total cash outlay of ₹81 crore. The offer will be conducted through a tender route with a record date of December 24, 2025. Eligible shareholders can tender 25 shares for every 103 shares held as of the record date.
Key Highlights
Buyback of 3,00,00,000 equity shares at a fixed price of ₹27 per share
Total buyback size is ₹81 crore, representing 13.38% of the existing total paid-up equity capital
Entitlement ratio set at 25 equity shares for every 103 shares held on the Record Date (Dec 24, 2025)
The buyback window is scheduled to open on December 31, 2025, and close on January 06, 2026
The offer size is 9.00% of the aggregate paid-up equity capital and free reserves as of March 31, 2025
👀 What to Watch
Eligible shareholders should consider tendering their shares if the market price remains below the ₹27 buyback price to realize immediate gains. Long-term investors may benefit from the 13.38% reduction in equity, which is likely to be accretive to Earnings Per Share (EPS).
Nectar Lifesciences to Sell Capsule Unit for INR 19.90 Crore via Slump Sale
Nectar Lifesciences Limited (NECLIFE) has executed a Business Transfer Agreement to sell its Empty Hard Gelatin Capsule manufacturing unit located in Baddi, Himachal Pradesh. The transaction is valued at INR 19.90 crore and will be executed as a slump sale on a going concern basis to Capnest Health Care Private Limited. The unit is a relatively small part of the company's operations, contributing only 1.28% to total revenue and 2.25% to net worth in FY25. The company intends to redeploy the sale proceeds into new strategic projects and general corporate purposes.
Key Highlights
Sale consideration fixed at INR 19.90 crore plus takeover of accounts receivables and payables.
The divested unit contributed INR 21.32 crore to revenue (1.28% of total) in FY 2024-25.
The transaction is expected to be completed on or before April 30, 2026.
Sale proceeds will be utilized for strategic investments in new projects and corporate growth.
The buyer, Capnest Health Care, is a newly incorporated entity and not part of the promoter group.
👀 What to Watch
The divestment involves a non-core asset with minimal impact on overall revenue. Investors should monitor the company's future announcements regarding the specific 'new projects' where the proceeds will be invested to assess long-term growth potential.
NECLIFE: Corrigendum for Buyback of Shares Public Announcement
Nectar Lifesciences Limited has announced a corrigendum to its public announcement regarding the buyback of equity shares. The corrigendum was published in Business Standard (English and Hindi editions) and Desh Sewak (Punjabi edition) on December 10, 2025. This announcement follows the initial public announcement for the buyback, which was disclosed on December 05, 2025. Investors should review the corrigendum for any revisions to the buyback details.
Key Highlights
Corrigendum to Buyback Public Announcement dated December 09, 2025
Published in Business Standard (English and Hindi) on December 10, 2025
Published in Desh Sewak (Punjabi) on December 10, 2025
Original Public Announcement disclosed on December 05, 2025
👀 What to Watch
Investors should review the details of the buyback corrigendum for any changes to the original announcement. Monitor company disclosures for further updates on the buyback process.
NECLIFE announces Buyback of 3,00,00,000 shares at ₹27 per share
Nectar Lifesciences Limited (NECLIFE) has announced a buyback of its equity shares. The company plans to buy back 3,00,00,000 fully paid-up equity shares, representing 13.38% of the total number of equity shares. The buyback price is set at ₹27 per equity share, payable in cash, for a total consideration not exceeding ₹81,00,00,000. The buyback will be executed through a tender offer route on a proportionate basis from the equity shareholders as of the record date, December 24, 2025. Promoters have indicated they will not participate in the buyback.
Key Highlights
Buyback of 3,00,00,000 equity shares
Buyback price of ₹27 per equity share
Total buyback consideration not exceeding ₹81,00,00,000
Represents 13.38% of the total number of equity shares
Record date is December 24, 2025
👀 What to Watch
Shareholders should evaluate the buyback offer and decide whether to participate based on their individual investment strategies and assessment of the company's future prospects. Monitor the progress of the buyback and the company's financial performance.
NECLIFE appoints Sushil Kapoor as Director (Finance) & Buyback at ₹27
Nectar Lifesciences Limited (NECLIFE) announced the appointment of Mr. Sushil Kapoor as an additional Director and Wholetime Director (Finance) effective December 4, 2025. The board also approved a buyback of 3,00,00,000 equity shares at a price of ₹27 per share, totaling ₹81,00,00,000. This buyback represents up to 13.38% of the total paid-up equity share capital. The record date for the buyback is December 24, 2025, and promoters will not participate.
Key Highlights
Appointment of Mr. Sushil Kapoor as Director (Finance) effective December 4, 2025
Buyback of 3,00,00,000 Equity Shares
Buyback price of ₹27 per Equity Share
Total buyback size of ₹81,00,00,000
Buyback represents 13.38% of total paid-up equity share capital
👀 What to Watch
Shareholders should note the record date of December 24, 2025, for the buyback and consider whether to participate in the tender offer. Monitor the postal ballot process for the approval of Mr. Kapoor's appointment.
NECLIFE Announces Buyback Record Date: Dec 24, 2025
Nectar Lifesciences Limited (NECLIFE) has announced a buyback of equity shares for ₹81 crore at a price of ₹27 per share. The buyback involves 3,00,00,000 fully paid-up equity shares, representing up to 13.38% of the total number of equity shares. The record date for determining shareholder eligibility for the buyback is December 24, 2025. Promoters and promoter group members will not participate in the buyback.
Key Highlights
Buyback size of ₹81,00,00,000
Buyback price of ₹27 per equity share
Buyback of 3,00,00,000 equity shares
Buyback represents up to 13.38% of total equity shares
Record date fixed as December 24, 2025
👀 What to Watch
Shareholders should evaluate the buyback offer and decide whether to participate based on their individual investment strategies. Monitor the company's announcements for further details on the buyback process.
NECLIFE Board approves ₹81 Crore Buyback at ₹27 per share
Nectar Lifesciences Limited's board has approved a buyback of equity shares for ₹81 crore at a price of ₹27 per equity share. This buyback comprises 3,00,00,000 fully paid-up equity shares, representing up to 13.38% of the total paid-up equity share capital. The buyback will be executed via a tender offer, excluding Promoters and Promoter Group. The record date for determining shareholder eligibility is December 24, 2025.
Key Highlights
Buyback size of ₹81,00,00,000
Buyback price of ₹27 per equity share
Buyback of 3,00,00,000 equity shares
Represents up to 13.38% of total paid-up equity
Record date fixed as December 24, 2025
👀 What to Watch
Shareholders should evaluate the buyback offer and decide whether to participate based on their investment goals. Monitor the company's announcements regarding the buyback process.
